Nestlé S.A. (NESN.SW)
| Previous Close | 91.72 |
| Open | 92.50 |
| Bid | 92.32 x 0 |
| Ask | 92.36 x 0 |
| Day's Range | 92.12 - 93.00 |
| 52 Week Range | 89.52 - 108.50 |
| Volume | |
| Avg. Volume | 4,028,116 |
| Market Cap | 241.878B |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | 21.83 |
| EPS (TTM) | 4.23 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 3.00 (3.27%) |
| Ex-Dividend Date | Apr 22, 2024 |
| 1y Target Est | 106.30 |
Insider MonkeyNestlé (NSRGY): Do Analysts Recommend This Ice Cream Stock In 2024?
We recently compiled a list of the 11 Best Ice Cream Stocks to Invest In 2024. In this article, we are going to take a look at where Nestlé (OTC:NSRGY) stands against the other ice cream stocks. Regarded as the most favorite dessert globally, ice cream has its popularity game quite high in the U.S. […]
The Telegraph‘Ozempic face’ supplements to combat side effects of rapid weight loss
Nestlé is to target “Ozempic face” by selling dietary supplements to counteract the effects of weight-loss drugs.
ReutersNestle, Coke take cautious approach to catering to Ozempic users
NEW YORK (Reuters) -Nestle's new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters. The world's largest food maker is keeping the names of the drugs off the packaging due to regulatory concerns, Tom Moe, Nestle USA's president of meals, said in a recent interview. Nestle will instead market its Vital Pursuit line of $5-and-under frozen meals on social media, he said.
